SEC Form 10-Q filed by Amgen Inc.
$AMGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/20/2025 | $288.00 | Neutral | Guggenheim |
| 4/22/2025 | $305.00 | Neutral | Cantor Fitzgerald |
| 12/10/2024 | $256.00 | Underperform | BofA Securities |
| 11/15/2024 | Peer Perform | Wolfe Research | |
| 11/14/2024 | $335.00 | Neutral | Citigroup |
| 10/17/2024 | $380.00 | Outperform | Bernstein |
| 10/14/2024 | $320.00 → $333.00 | Buy → Hold | Truist |
| 9/27/2024 | $405.00 | Overweight | Cantor Fitzgerald |